The aim of the oncNGS pre-commercial procurement (PCP) is to develop affordable integrated solutions that can completely transform cancer patients' experience through predictive diagnosis, prognosis and theranosis capabilities based on Next Generation Sequencing (NGS) technology. OncNGS invites entrepreneurs, start-ups, companies, academia, and other relevant stakeholders to present their proposal for designing, developing and testing their solution that will be provided during this PCP.

The oncNGS PCP Call for tender is now open. Deadline for submission is 17 October 2022.

• The contract notice of the Pre-commercial procurement has been published at Tenders Electronic Daily here.
• The complete tender documentation is available here.
• Bidders can participate in a joint tender and look for suitable partners through oncNGS' matchmaking page.
• A Frequently Asked Questions page is also available on the oncNGS website.

All detailed information can be found on oncNGS' website.

Background information: The Horizon 2020 financed project 'OncNGS'  is a strong consortium composed of 8 buyers from 5 EU Member States (Sciensano ; Institut Jules Bordet (Belgium) ; Institut Curie ; Hospices Civils de Lyon (France) ; Charite Universitaetsmedizin ; Ludwig Maximilians Universitaet Muenchen (Germany) ; Alleanza Contro il Cancro (Italy) ; Institut Catala d’Oncologia (Spain)) and supported by 6 entities with wide experience in their fields (Agència de Qualitat i Avaluació Sanitàries de Catalunya ; the Belgian Cancer Registry ; Institut National du Cancer ; Instituto de Investigación Biomédica de Salamanca ; Valle de Hebrón Instituto de Oncología ; De Clercq & Partners).